News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
500,031 Results
Type
Article (34554)
Company Profile (40)
Press Release (465437)
Section
Business (145123)
Career Advice (2323)
Deals (26528)
Drug Delivery (70)
Drug Development (69766)
Employer Resources (134)
FDA (12805)
Job Trends (11525)
News (258602)
Policy (25608)
Tag
Academia (2387)
Africa (674)
Alabama (25)
Allergies (33)
Alliances (35935)
Alzheimer's disease (1084)
Antibody-drug conjugate (ADC) (45)
Approvals (12753)
Arizona (84)
Artificial intelligence (46)
Asia (31093)
Australia (6589)
Bankruptcy (292)
Best Places to Work (9123)
Biosimilars (37)
C2C Services and Suppliers (51145)
California (697)
Canada (555)
Cancer (169)
Career advice (1949)
CAR-T (26)
Cell therapy (58)
China (36)
Clinical research (54313)
Collaboration (47)
Colorado (29)
COVID-19 (2245)
Cystic fibrosis (50)
Diabetes (28)
Diagnostics (5087)
Diversity, equity & inclusion (38)
Drug pricing (44)
Earnings (50170)
Employer resources (118)
Europe (68619)
Events (67247)
Executive appointments (27)
FDA (12843)
Florida (89)
Funding (34)
Gene therapy (51)
GLP-1 (443)
Government (3857)
Healthcare (15189)
Hotbed/Location (336004)
Idaho (41)
Illinois (145)
Indiana (86)
Infectious disease (2256)
Inflammatory bowel disease (72)
Interviews (509)
IPO (11733)
Job creations (2413)
Job search strategy (1617)
Kansas (71)
Layoffs (332)
Legal (5282)
Liver cancer (48)
Lung cancer (42)
Maine (36)
Management (46)
Manufacturing (36)
Maryland (222)
Massachusetts (339)
Medical device (9858)
Medtech (9860)
Mergers & acquisitions (14540)
Metabolic disorders (144)
Neuroscience (1165)
New Jersey (54)
New York (73)
NextGen Class of 2024 (5180)
Non-profit (3757)
North Carolina (122)
Obesity (91)
Opinion (160)
Parkinson's disease (29)
Patents (31)
Peanut (29)
Pennsylvania (45)
People (47599)
Phase I (16611)
Phase II (23931)
Phase III (18347)
Policy (29)
Postmarket research (2179)
Preclinical (6704)
Rare diseases (68)
Real estate (3781)
Recruiting (50)
Regulatory (17126)
Research institute (1971)
Resumes & cover letters (336)
South America (929)
Startups (2507)
Texas (68)
United States (2379)
Vaccines (346)
Washington State (85)
Weight loss (89)
Date
Today (45)
Last 7 days (416)
Last 30 days (1601)
Last 365 days (31701)
2024 (17923)
2023 (33032)
2022 (43276)
2021 (46260)
2020 (44762)
2019 (38061)
2018 (28841)
2017 (25873)
2016 (24457)
2015 (28635)
2014 (21272)
2013 (17138)
2012 (18309)
2011 (19387)
2010 (17118)
500,031 Results for "optinose as".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Optinose Announces $55 Million Registered Direct Offering
Optinose announced that it has entered into agreements for the sale of approximately $55 million of its common stock and pre-funded common stock warrants to a group of existing and new institutional investors in a registered direct offering.
May 9, 2024
·
8 min read
Business
Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended March 31, 2024, and provided recent operational highlights.
May 14, 2024
·
11 min read
Business
Optinose Announces Reporting Date for First Quarter 2024 Financial Results
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the first quarter 2024 and corporate updates, before market open, on Tuesday, May 14, 2024.
May 10, 2024
·
1 min read
Pharm Country
Optinose to Present at the Needham Virtual Healthcare Conference - April 04, 2024
Optinose announced that members of its management team will present a company overview and business update at the Needham Virtual Healthcare Conference on April 10, 2024 at 2:15 p.m. ET.
April 4, 2024
·
1 min read
Business
Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024
Optinose today announced corporate updates detailing its commercial plans and expectations for XHANCE ® (fluticasone propionate) following the recent FDA approval of a new indication for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 year of age and older.
April 25, 2024
·
8 min read
Pharm Country
Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ on May 20, 2024 at 11:30 a.m. ET.
May 17, 2024
·
1 min read
Business
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational highlights.
March 7, 2024
·
11 min read
Drug Development
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Optinose today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice1.
January 18, 2024
·
11 min read
Business
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial ResultsConference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before market open on Thursday, March 7, 2024.
February 29, 2024
·
1 min read
Business
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, reported financial results for the quarter ended September 30, 2023, and provided operational updates.
November 9, 2023
·
11 min read
1 of 50,004
Next